Wickham Laboratories will be exhibiting at Pharmig’s 26th annual conference held on the 28th & 29th November at the Belfry Hotel, Nottingham. This year’s event will bring together an array of industry experts and regulators to discuss the latest research and findings within the pharmaceutical microbiology industry. The conference programme will include the following topics among others: • Water system biofilms • Uses and applications of microbiological culture media • Sterility assurance strategies • Aseptic manufacturing • Endotoxin testing • Fungal and bacterial cleanroom excursions •…

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 30, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 researchers from 80 countries, will take place from November 3-7, in San Diego, California. Continued Commitment to Scientific Excellence Throughout the…

WILMINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Oct. 25, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms. This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20181025005076/en/ This partnership will grant Charles River’s clients access to Distributed Bio’s antibody libraries and integrated antibody optimization…

Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets.  Arecor is pleased to announce the successful outcome of the opposition proceedings at the European Patent Office in relation to a key patent of the Company’s broad portfolio that leads to the prevention of aggregation of therapeutic proteins during…

Cambridge, UK, 30 October 2018: TTP Ventus, manufacturer of the Disc Pump range of multi-award-winning micropumps, today introduced its XP Series, the latest pump products in the Company’s strategic development pipeline. The XP Series offers enhanced performance, efficiency, and a wide operational temperature range to support a more diverse range of applications across the medical, life sciences, environmental and defence sectors. TTP Ventus’ Disc Pump platform delivers high pressure and flow, silent operation, rapid response time, accuracy, infinite turn-down ratio and ultra-smooth flow in a…

Cambridge, UK, 24 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised to date to £12m.  The company, which was founded in 2016 to develop transformational technology developed at the Sanger Institute, has made rapid progress in developing a unique capability to culture, characterise and phenotype the majority of a patient’s gut bacteria, enabling the precise association of…

A brand-new lab facility is soon to be opening within the heart of Newcastle’s £350m urban development scheme - Newcastle Helix. The Biosphere will provide a home for ambitious companies within life sciences and innovation, research and development. This is all part of the city’s wider commitment to support economic development and growth within the life sciences sector. The new 90,000 sq. ft purpose-built £25m facility will contain both commercial laboratory and office spaces. As well as satisfying commercial laboratory demand, a conferencing facility for up to 80 people will offer a space…

AMSBIO has added an important new product to its immunotherapy range - a PD-L2 / TCR activator - CHO Recombinant Cell Line.PD-L2 is one of the key players in immune checkpoint therapy, which is the focus of the 2018 Nobel Prize for Physiology & Medicine . This work pioneered by Professor James P Allison from the USA and Professor Tasuku Honjo from Japan, has led to treatments for cancers, such as melanoma, lung cancer and others based upon immune checkpoint therapy.The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its…

GiroNEX Ltd – a new Cambridgeshire-based technology spin-out – has announced today first details of a novel precision powder dispensing technology that could significantly increase the pharmaceutical industry’s ability to offer patient-specific dosing for more effective treatment of specific conditions.The new GiroNEX technology can quickly dispense from 0.1 milligrams to 5 grams of pharmaceutical or other chemical powders into vials or capsules and with accuracies of 2% or better across the complete weight range.  This innovative new approach has been specifically developed to target…

Genomics England names Congenica as Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service 17 October 2018 Cambridge Innovation Capital plc (CIC) notes that its portfolio company, Congenica, has been awarded a multi-year contract by Genomics England to be a provider of Diagnostic Decision Support Services in relation to the delivery of the UK National Health Service’s (NHS) world-leading Genomic Medicine Service.Genomics England carried out a rigorous evaluation of all the leading providers of diagnostic decision support solutions for genomics from…